Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year


IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.741
Source Normalized Impact per Paper (SNIP) 2014: 1.011
Impact per Publication (IPP) 2014: 2.310

VolumeIssuePage

Issues

Changes of the Coagulation and Fibrinolysis System in Malignancy: Their possible Impact on Future Diagnostic and Therapeutic Procedures

Wolfgang Korte

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 38, Issue 8, Pages 679–692, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2000.099, June 2005

Publication History

Published Online:
2005-06-01

Abstract

The interaction between malignant cell growth and the coagulation and fibrinolysis system has been a well known phenomenon for decades. During recent years, this area of research has received new attention. Experimental data suggest a role for the coagulation and fibrinolysis system in tumor development, progression and metastasis. Also, clinical research suggests that targeting the coagulation system or fibrinolysis system might influence the course of malignant disease beneficially. This paper reviews data on various hemostatic and fibrinolytic parameters in malignancy; the possible use of such parameters as risk markers in oncology patients; and possible targets of anti-neoplastic therapies using anticoagulant and/or antifibrinolytic strategies. Current evidence suggests that the tissue factor/factor VIIa pathway mediates the most abundant procoagulant stimulus in malignancy via the increase in thrombin generation. Tissue factor has been suggested to mediate pro-metastatic properties via coagulation-dependent and coagulation-independent pathways; tissue factor has also been implicated in tumor neo-angiogenesis. However, so far no model has been validated that would allow the use of tissue factor in its soluble or insoluble form as a marker for risk stratification in tumor patients. On the other hand, there is now good evidence that parts of the fibrinolytic system, such as urokinase-type plasminogen activator and its receptor (“uPAR”), can be used as strong predictors of outcome in several types of cancer, specifically breast cancer. Observation of various treatment options in patients with thomboembolic disease and cancer as well as attempts to use anticoagulants and/or therapies modulating the fibrinolytic system as anti-neoplastic treatment strategies have yielded exciting results. These data indicate that anticoagulant therapy, and specifically low molecular weight heparin therapy, is likely to have anti-neoplastic effects; and that their use in addition to chemotherapy will probably improve outcome of tumor treatment in certain types of cancer. However, the body of clinical data is still relatively small and the question whether or not we should routinely consider the coagulation and/or fibrinolysis system as therapeutic targets in cancer patients is yet to be answered.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
J. Djukic-Filimonovic, C. Tulic, Z. Dzamic, B. Krivic, B. Milkovic, B.B. Markovic, and J. Hadzi-Djokic
Acta chirurgica iugoslavica, 2007, Volume 54, Number 4, Page 93
[2]
Jan Walter, Linn L. Handel, Michael Brodhun, Denise van Rossum, Uwe-Karsten Hanisch, Lutz Liebmann, Frank Heppner, Roland Goldbrunner, Arend Koch, and Susanne A. Kuhn
Journal of Cancer Research and Clinical Oncology, 2012, Volume 138, Number 1, Page 141
[3]
Aydan Eroğlu, Ayşenur Öztürk, and Nejat Akar
Breast Cancer, 2011, Volume 18, Number 4, Page 282
[4]
Joseph S. Palumbo and Jay L. Degen
Thrombosis Research, 2007, Volume 120, Page S22
[5]
J. Lykke and H.J. Nielsen
European Journal of Surgical Oncology (EJSO), 2003, Volume 29, Number 5, Page 417
[6]
L. R. ZACHARSKI
Journal of Thrombosis and Haemostasis, 2011, Volume 9, Number 9, Page 1804
[7]
Vladimir Bobek, Daniela Pinterova, Katarina Kolostova, Michael Boubelik, Joshua Douglas, Petr Teyssler, Jiri Pavlasek, and Josef Kovarik
Cancer Letters, 2006, Volume 237, Number 1, Page 95
[8]
Leo R Zacharski
Cancer Letters, 2002, Volume 186, Number 1, Page 1
[9]
Marcello De Cicco
Critical Reviews in Oncology/Hematology, 2004, Volume 50, Number 3, Page 187
[10]
Dimitris Zacharoulis, Constantine Hatzitheofilou, Evangelos Athanasiou, and Stergios Zacharoulis
Expert Review of Anticancer Therapy, 2005, Volume 5, Number 4, Page 645
[11]
Amulya K. Saxena and Cornelia van Tuil
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 2007, Volume 17, Number 6, Page 545
[12]
Aldo Profumo, Barbara Cardinali, Carla Cuniberti, and Mattia Rocco
ELECTROPHORESIS, 2005, Volume 26, Number 3, Page 600
[13]
Jakob Lykke and Hans J�rgen Nielsen
Journal of Surgical Oncology, 2004, Volume 88, Number 4, Page 269

Comments (0)

Please log in or register to comment.